These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
57 related articles for article (PubMed ID: 6689400)
1. [Dose-response relationship of intravenous administration of benzquinamide hydrochloride for suppression of cytostatic-induced emesis]. Nietsch P Arzneimittelforschung; 1983; 33(12):1694-5. PubMed ID: 6689400 [TBL] [Abstract][Full Text] [Related]
2. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting. Voravud N; Sriuranpong V J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975 [TBL] [Abstract][Full Text] [Related]
3. Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy. Cheirsilpa A; Ratanatharathorn V; Sinlarat P; Chindavijak K; Lousoontornsiri W; Chakrapee-Sirisuk S; Srimuninimit V J Med Assoc Thai; 1994 Apr; 77(4):201-6. PubMed ID: 7844494 [TBL] [Abstract][Full Text] [Related]
4. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience. Sorbe BG Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123 [TBL] [Abstract][Full Text] [Related]
5. Phase II trial of tropisetron and dexamethasone in the prevention of cisplatin-induced emesis. Voravud N; Suwanrusmee H J Med Assoc Thai; 2000 Jun; 83(6):668-75. PubMed ID: 10932495 [TBL] [Abstract][Full Text] [Related]
6. Comparison of oral versus intravenous ramosetron in prevention of acute cisplatin-induced emesis: a randomized controlled trial. Tantipalakorn C; Srisomboon J; Thienthong H; Pantusart A; Suprasert P; Saereesongkhun C; Eamtang S; Sutthichat A; Pautad N J Med Assoc Thai; 2004 Feb; 87(2):119-25. PubMed ID: 15061293 [TBL] [Abstract][Full Text] [Related]
7. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488 [TBL] [Abstract][Full Text] [Related]
8. [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin]. Tanimura S; Banba J; Tomoyasu H; Masaki M Gan To Kagaku Ryoho; 1998 Dec; 25(14):2275-81. PubMed ID: 9881085 [TBL] [Abstract][Full Text] [Related]
9. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy. Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy. Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429 [TBL] [Abstract][Full Text] [Related]
11. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis]. Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810 [TBL] [Abstract][Full Text] [Related]
12. Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesis. Martoni A; Piana E; Strocchi E; Angelelli B; Guaraldi M; Zamagni C; Camaggi CM; Pannuti F Anticancer Res; 1998; 18(4B):2799-803. PubMed ID: 9713464 [TBL] [Abstract][Full Text] [Related]
13. Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy. Chen PT; Liaw CC Chang Gung Med J; 2008; 31(2):167-74. PubMed ID: 18567417 [TBL] [Abstract][Full Text] [Related]
14. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group. Rubenstein EB; Gralla RJ; Hainsworth JD; Hesketh PJ; Grote TH; Modiano MR; Khojasteh A; Kalman LA; Benedict CR; Hahne WF Cancer; 1997 Mar; 79(6):1216-24. PubMed ID: 9070501 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study. Tsavaris N; Kosmas CH; Vadiaka M; Kontos A; Katsorida M; Dimitrakopoulos A; Zerai A; Koufos CH J Exp Clin Cancer Res; 2001 Mar; 20(1):29-34. PubMed ID: 11370826 [TBL] [Abstract][Full Text] [Related]
17. Specific antiemetics for specific cancer chemotherapeutic agents: haloperidol versus benzquinamide. Neidhart JA; Gagen M; Young D; Wilson HE Cancer; 1981 Mar; 47(6):1439-43. PubMed ID: 7013968 [TBL] [Abstract][Full Text] [Related]
18. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394 [TBL] [Abstract][Full Text] [Related]
19. Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone. Hesketh PJ; Gandara DR; Hesketh AM; Edelman M; Webber LM; McManus M; Hainsworth JD Cancer J Sci Am; 1997; 3(3):180-3. PubMed ID: 9161784 [TBL] [Abstract][Full Text] [Related]
20. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Hickok JT; Roscoe JA; Morrow GR; King DK; Atkins JN; Fitch TR Cancer; 2003 Jun; 97(11):2880-6. PubMed ID: 12767103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]